Pharmacoeconomic comparison of Helicobacter pylori eradication regimens

Sancar M., Izzettin F. V., RABUŞ Ş., BEŞIŞIK S. F., Tozun N., Dulger G.

PHARMACY WORLD & SCIENCE, cilt.28, sa.4, ss.207-214, 2006 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 4
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1007/s11096-006-9021-y
  • Dergi Adı: PHARMACY WORLD & SCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED)
  • Sayfa Sayıları: ss.207-214
  • Anahtar Kelimeler: cost-effectiveness, eradication regimens, gastritis, Helicobacter pylori, peptic ulcer, pharmacoeconomics, COST-EFFECTIVENESS ANALYSIS, PEPTIC-ULCER DISEASE, DUODENAL-ULCER, ANTIBIOTIC-RESISTANCE, BISMUTH SUBCITRATE, TRIPLE THERAPY, INFECTION, OMEPRAZOLE, MANAGEMENT, AMOXICILLIN
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background Helicobacter pylori is the most important etiologic agent for development of peptic ulcer, chronic gastritis and gastric carcinomas. It is now well established that H. pylori eradication treatment is more cost-effective than acid suppressing therapies alone for the treatment of peptic ulcer disease. However, the comparative cost-effectiveness of various H. pylori eradication regimens is still not clear.